Search Results - "Monique EMM Bos"

Patterns of care over 10 years in young breast cancer patients in the Netherlands, a nationwide population-based study by Maliko, Nansi, Bijker, Nina, Bos, Monique EMM, Wouters, Michel WJM, Vrancken Peeters, Marie-Jeanne TFD

“…Each year, around 600 young (<40 years) breast cancer (BC) patients are registered in the national NABON Breast Cancer Audit (NBCA). The aim of this study is…”
Get full text

Association between initiation of adjuvant chemotherapy beyond 30days after surgery and overall survival among patients with triple‐negative breast cancer by Heeg, Erik, Perla J Marang‐van de Mheen, Van Maaren, Marissa C, Schreuder, Kay, Tollenaar, Rob AEM, Siesling, Sabine, Monique EMM Bos, Marie‐Jeanne TFD Vrancken Peeters

“…Delayed time to chemotherapy (TTC) is associated with decreased outcomes of breast cancer patients. Recently, studies suggested that the association might be…”
Get full text

Abstract OT2-01-08: SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, HR+ HER2- advanced breast cancer by Almekinders, Cornelia AM, Konings, Inge RHM, van der Noort, Vincent, van den Berg, Susan M, Bos, Monique EMM, Dezentjé, Vincent O

“…Goal To investigate the efficacy of alpelisib added to fulvestrant beyond progression in patients with HR+ HER2- advanced breast cancer (ABC). Background The…”
Get full text

Abstract OT2-15-01: COntinue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study by Almekinders, Cornelia AM, Steenbruggen, Tessa G, Mandjes, Ingrid A., Lopez-Yurda, Marta, Bos, Monique EMM, Wiersma, Terry G, Sonke, Gabe S.

“…Background Patients with metastatic breast cancer (MBC) are usually treated with palliative systemic therapy until progression or unacceptable toxicity. When…”
Get full text